Relapse Clinical Trial
Official title:
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.
In this single-center, open-label, nonrandomized, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19+ B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled. CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB, will be administered by i.v. injection in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. Side effects of CD19 CAR T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells therapy in patients with relapsed or refractory CD19 positive B-cell lymphoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
| Completed |
NCT00306813 -
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT01956695 -
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT05926167 -
Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
|
||
| Recruiting |
NCT03710512 -
Evaluation of Early Relapse After Mandibular Lengthening Surgery
|
||
| Recruiting |
NCT04921540 -
Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA
|
N/A | |
| Completed |
NCT05250765 -
Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT.
|
N/A | |
| Not yet recruiting |
NCT03830827 -
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
|
Phase 4 | |
| Completed |
NCT05915273 -
Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers
|
N/A | |
| Active, not recruiting |
NCT04389879 -
CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial
|
N/A | |
| Recruiting |
NCT06417346 -
Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients
|
N/A | |
| Recruiting |
NCT06417359 -
Comparison of Mesh Fixation and Non-Fixation in eTEP
|
N/A | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01481701 -
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
|
Phase 2 | |
| Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
| Recruiting |
NCT04723901 -
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04994626 -
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
|
Phase 2 | |
| Recruiting |
NCT06292364 -
Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis
|
N/A | |
| Enrolling by invitation |
NCT05591703 -
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
|
||
| Active, not recruiting |
NCT00299923 -
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
|
Phase 3 |